Navigation Links
Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Date:3/3/2009

SEATTLE, March 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its fourth quarter and year end 2008 financial results on Monday, March 9, 2009 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.

The discussion is planned for a live webcast and can be accessed at www.oncothyreon.com under the "News & Events" section. It is expected that the archive of the webcast will be available approximately one hour after completion of the discussion and will be posted on the Oncothyreon website for 30 days.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon to present at BIO CEO & Investor Conference 2009
2. Oncothyreon reports third quarter 2008 financial results
3. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
5. Oncothyreon to present at BIO Investor Forum 2008
6. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
7. Oncothyreon announces prioritization plan for development programs
8. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
9. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
10. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
11. Oncothyreon to receive milestone payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):